Gastroenterology and Hepatology from Bed to Bench

Saad Zaghloul M.A, Abadi A.H, Abdelaziz A.I. Functional evalution of imatinib mesylate in hepatocellular carcinoma cells. Recent patents on biomarkers 2013; 3: 65-71.

Marin J.J.G, Castano B, Martinez Becerra P, Rosales R, Monte M.J. Chemotherapy in the treatment of primary liver tumors. Cancer therapy 2008; 6:711-728.

Buxton I.L.O, Yokdang N. Extracellular Nm23 Signaling in breast cancer: incommodus verum. Cancers 2011;3: 2844-57.

Howlett A.R, Petersen O.W, Steeg P.S, Bissell M.J. Novel function for the nm23-Hl gene: overexpression in human breast carcinoma cells leads to the formation of basement membrane and growth arrest. J Natl Cancer Inst 2010; 86: 1838-44.

Shangyang Sh, Xu,He B, Lan X, Wang Q. Nm23-H1 suppresses hepatocarcinoma cell adhesion and migration on fibronectin by modulating glycosylation of integrin beta 1. J Exp Clin Cancer Res 2010; 29:93.

Blay J.Y, Rutkowski P. Adherence to imatinib therapy in patients with gastrointestinal stromal tumors, Cancer Treat. Rev 2014;40: 242-247.

Sadat Shandiz S.A, Shafiee Ardestani M, Irani Sh, Shahbazzadeh D. Imatinib induces down regulation of Bcl-2 an anti-apoptotic protein in prostate cancer PC-3 cell line. Adv Stud Biol 2015;7: 17-27.

Weigel M.T, Dahmke L, Schem Ch, Bauerschlag D.O, Weber K, Niehoff P, et al. In vitro effects of imatinib mesylate on radiosensitivity and chemosensitivity of breast cancer cells, BMC Cancer 2010;10: 412.

Bansa Sh. Is imatinib still the best choice as first-line oral TKI. South Asian J Cancer 2014; 3:83–86.

Constance K, Woessner J.E, Matissek D.W, Mossalam K.J, Lim C.S. Enhanced and selective killing of chronic myelogenous leukemia cells with an engineered BCR-ABL binding protein and imatinib, Molecular Pharmacology 2012; 9: 3318–29.

Ronald Hassler M, Vedadinejad M, Flechl B, Haberler Ch, Preusser M, Andreas Hainfellner J, et al. Response to imatinib as a function of target kinase expression in recurrent glioblastoma. Springer Plus 2014;3: 111.

Ohishi J, Aoki M, Nabeshima K, Suzumiya J, Takeuchi T, Ogose A, et al. Imatinib mesylate inhibits cell growth of malignant peripheral nerve sheath tumors in vitro and in vivo through suppression of PDGF-. BMC cancer 2013;13:224.

Thomas M. Molecular targeted therapy for hepatocellular carcinoma. J Gastroenterol 2009;44, 136-41.

Groot J.W.B, Menacho I.P, Schepers H, Drenth-Diephuis L.J, Osinga J, Plukker J.T.M, Links T.P, et al. Cellular effects of imatinib on medullary thyroid cancer cells harboring multiple endocrine neoplasia Type 2A and 2B associated RET mutations. Surgery 2006;139: 806-814.

Vogiatzi P, Cassone M, Claudio L, Claudio P.P. Targeted therapy for advanced prostate cancer: Looking through new lenses. Drug News Prospect 2009;22: 593-601.

Kinoshita K, Nakagawa K, Hamada J, Hida Y, Tada M, Kondo S, et al. Imatinib mesylate inhibits the proliferation-stimulating effect of human lung cancer-associated stromal fibroblasts on lung cancer cells, Int J Onco 2010; 37: 869-877.

Bhavinkumar B.P, Yin A.H, Frolo X. Li, Vanderveer L, Slater C, Schilder R.J, et al. Molecular mechanisms of action of imatinib mesylate in human ovarian cancer: a proteomic analysis. Cancer Genomics Proteomics 2008; 5:137-150.

Zhang Q, McCorkle J.R, Novak M. Metastasis suppressor function of NM23-H1 requires its 30-50 exonuclease activity. Int J Cancer 2001; 128: 40-50.

Yoshida B.A, Sokoloff M.M, Welch D.R, Rinker-Shaeffer C.W. Metastasis-suppresor Genes: A review and perspective on an emerging field. Journal of the National Institute 2000; 92:1717-1730.

Jung SH, Paek Y.W, Moon K.S, Wee S.Ch, Ryu H.H, Jeong Y.I, et al. Expression of Nm23 in gliomas and its effect on migration and invasion in vitro. Anticancer Research 2006;26: 545-553.

Jung H, Seong H.A. NM23-H1 tumor suppressor and its interacting partner STRAP activate p53 function. J Biol Chem 2007; 30:35293-307.

Lin K.H, Lin Y.W, Lee H.F, Liu W.L, Chen S.T, Chang K.S, et al. Increased invasive activity of human hepatocellular carcinoma cells is associated with an overexpression of thyroid hormone beta 1 nuclear receptor and low expression of the anti-metastatic nm23 gene. Cancer Lett 1995; 98:89-95.

Fujimoto Y, Ohtake T, Nishimori H, Ikuta K, Ohhira M, Ono M, et al. Reduced expression and rare genomic alteration of nm23-H1 in human hepatocellular carcinoma and hepatoma cell lines. J Gastroenterol 1998; 33: 368–375.

Yamaguchi A, Urano T, Goi T, Takeuchi K, Niimoto S, Nakagawara G, et al. Expression of human nm23-H1 and nm23-H2 proteins in Hepatocellular carcinoma. Cancer 1994; 73: 2280-2284.